ABBV vs JNJ: stock comparison and AI forecast
Abbvie Inc. (ABBV) and Johnson & Johnson (JNJ) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABBV Abbvie Inc.
- Price
- $291.31 +43.7% · 6M
- Market Cap
- $514.78B
- P/E Ratio
- 44.6x
- Size
- mega-cap
- AI Forecast
JNJ Johnson & Johnson
- Price
- $276.22 +24.1% · 6M
- Market Cap
- $664.95B
- P/E Ratio
- 42.0x
- Size
- mega-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- JNJ is 1.3 times larger than ABBV by market capitalization ($664.95B against $514.78B).
- JNJ trades at 42.0 times trailing earnings, ABBV at 44.6 times.
- Over the last six months ABBV returned +43.7% and JNJ +24.1%.
- JNJ turns 16.2% of its revenue into net income, against 15.7% for ABBV.
- ABBV yields 2.36% in dividends and JNJ 1.91%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABBV | JNJ |
|---|---|---|
| Market Cap | $514.78B | $664.95B |
| P/E Ratio | 44.61x | 41.98x |
| P/B Ratio | – | 8.16x |
| Dividend Yield | 2.36% | 1.91% |
| EPS | $6.53 | $6.58 |
| Book Value/Share | – | $33.87 |
| Revenue/Share | $37.36 | $41.26 |
| FCF/Share | $10.68 | $8.55 |
Profitability & Margins
| Metric | ABBV | JNJ |
|---|---|---|
| ROE | – | 19.7% |
| ROA | 7.0% | 8.2% |
| ROIC | 20.3% | – |
| Gross Margin | 73.7% | 67.6% |
| Operating Margin | 32.2% | – |
| Net Margin | 15.7% | 16.2% |
| EBT Margin | 19.4% | 17.9% |
| Tax Rate | 19.2% | 9.3% |
Financial Health
| Metric | ABBV | JNJ |
|---|---|---|
| Current Ratio | 0.87x | 1.02x |
| Quick Ratio | 0.75x | 0.74x |
| D/E Ratio | – | 1.42x |
| Financial Leverage | – | 2.42x |
| Interest Coverage | 7.8x | 42.2x |
| Working Capital | -$5.62B | $894M |
Cash Flow
| Metric | ABBV | JNJ |
|---|---|---|
| Operating Cash Flow | $20.09B | $26.16B |
| Free Cash Flow | $18.87B | $20.59B |
| Capital Spending | -$1.22B | -$5.57B |
| OCF Growth YoY | -3.7% | 8.1% |
| FCF Growth YoY | -4.1% | 5.1% |
| FCF/Sales | 28.6% | 20.7% |
| CapEx/Sales | 1.8% | 5.6% |
Operational Efficiency
| Metric | ABBV | JNJ |
|---|---|---|
| Asset Turnover | 0.45x | 0.50x |
| Receivables Turnover | 4.9x | 5.2x |
| Inventory Turnover | 3.3x | 2.1x |
| Fixed Assets Turnover | 11.1x | 4.1x |
| Days Sales Outstanding | 75 days | 70 days |
| Days Inventory | 112 days | 174 days |
| Payables Period | 724 days | 106 days |
| Cash Conversion Cycle | -538 days | 138 days |
Income Statement
| Metric | ABBV | JNJ |
|---|---|---|
| Total Revenue | $66.01B | $99.33B |
| Operating Income | $21.23B | – |
| Net Income | $10.34B | $16.09B |
| R&D Expense | $9.96B | $1.53B |
| SG&A Expense | $15.19B | $25.50B |
| Cost of Goods Sold | $17.35B | $32.22B |
Dividend & Shareholder Information
| Metric | ABBV | JNJ |
|---|---|---|
| Dividends Per Share | $6.87 | $5.28 |
| Payout Ratio | 105.2% | 80.2% |
| Shares Outstanding | 1767M | 2407M |
| Net Income Growth | 333.1% | -35.9% |
| EPS Growth | 380.1% | -36.5% |
ABBV vs JNJ: stock comparison and AI forecast
Which is bigger, ABBV or JNJ?
JNJ is 1.3 times larger than ABBV by market capitalization ($664.95B against $514.78B).
Which is cheaper on earnings, ABBV or JNJ?
JNJ trades at 42.0 times trailing earnings, ABBV at 44.6 times.
Which stock performed better over the last six months, ABBV or JNJ?
Over the last six months ABBV returned +43.7% and JNJ +24.1%.
Which one does Intratio's AI model rank higher, ABBV or JNJ?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.